MCID: SYS001
MIFTS: 86

Systemic Lupus Erythematosus

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus

MalaCards integrated aliases for Systemic Lupus Erythematosus:

Name: Systemic Lupus Erythematosus 57 38 12 76 25 54 75 37 29 6 3 15
Lupus Nephritis 57 12 53 37 55 44 15 73
Lupus Erythematosus, Systemic 12 44 73
Sle 57 25 75
Systemic Lupus Erythematosus, Susceptibility to 57 6
Lupus Nephritis, Susceptibility to 57 6
Disseminated Lupus Erythematosus 12 25
Libman-Sacks Disease 25 73
Lupus Erythematosus, Systemic, Susceptibility to 40
Systemic Lupus Erythematosus Susceptibility to 57
Sle - Lupus Erythematosus, Systemic 12
Lupus Erythematosus Systemic 55
Lupus Erythematosus, Discoid 73
Lupus Erythematosus 73
Lupus Vulgaris 73
Le Syndrome 25
Lupus 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
complement deficiency (e.g. c2 and c4 null alleles) are susceptible to developing sle
association between hla class ii alleles and presence of autoantibodies
onset between ages 16-55
female to male ratio 8-13:1


HPO:

32
systemic lupus erythematosus:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Systemic Lupus Erythematosus

NINDS : 54 Lupus (also called systemic lupus erythematosus) is a disorder of the immune system. Normally, the immune system protects the body against invading infections and cancers. In lupus, the immune system is over-active and produces increased amounts of abnormal antibodies that attack the body's tissues and organs. Lupus can affect many parts of the body, including the joints, skin, kidneys, lungs, heart, nervous system, and blood vessels. The signs and symptoms of lupus differ from person to person; the disease can range from mild to life threatening. Initial symptoms of lupus may begin with a fever, vascular headaches, epilepsy, or psychoses. A striking feature of lupus is a butterfly shaped rash over the cheeks. In addition to headache, lupus can cause other neurological disorders, such as mild cognitive dysfunction, organic brain syndrome, peripheral neuropathies, sensory neuropathy, psychological problems (including personality changes, paranoia, mania, and schizophrenia), seizures, transverse myelitis, and paralysis and stroke.

MalaCards based summary : Systemic Lupus Erythematosus, also known as lupus nephritis, is related to lupus erythematosus and systemic lupus erythematosus 16, and has symptoms including exanthema, pruritus and lupus-like rash. An important gene associated with Systemic Lupus Erythematosus is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways/superpathways are Systemic lupus erythematosus and NF-kappaB Signaling. The drugs Simvastatin and 4-Aminopyridine have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, t cells and skin, and related phenotypes are nephritis and psychosis

Disease Ontology : 12 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart.

Genetics Home Reference : 25 Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 53 Lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematous (SLE), commonly known as lupus. The symptoms of lupus nephritis include blood in the urine, a foamy appearance to the urine, high blood pressure, and swelling in any part of the body. This condition typically occurs in people aged 20 to 40 years. Treatment may involve medications to suppress the immune system, dialysis, or a kidney transplant. Visit our Web page on lupus for more information and resources.

OMIM : 57 Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies against nuclear, cytoplasmic, and cell surface molecules that transcend organ-specific boundaries. Tissue deposition of antibodies or immune complexes induces inflammation and subsequent injury of multiple organs and finally results in clinical manifestations of SLE, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures, and arthritis. Evidence strongly suggests the involvement of genetic components in SLE susceptibility (summary by Oishi et al., 2008). (152700)

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

UniProtKB/Swiss-Prot : 75 Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Wikipedia : 76 Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the... more...

Related Diseases for Systemic Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 lupus erythematosus 36.6 BANK1 C4A C4B CR2 CTLA4 DNASE1
2 systemic lupus erythematosus 16 36.2 C4A DNASE1
3 pediatric systemic lupus erythematosus 35.9 C4A C4B STAT4
4 rheumatoid arthritis 33.3 CTLA4 MALAT1 PTPN22 STAT4 TNF
5 autoimmune disease 33.1 CTLA4 FCGR2A FCGR2B PDCD1 PTPN22 STAT4
6 wegener granulomatosis 32.2 CTLA4 PTPN22 STAT4 TNF
7 anca-associated vasculitis 31.8 CTLA4 TNF
8 celiac disease 1 31.8 CTLA4 PTPN22 TNF
9 alopecia areata 31.7 CTLA4 PTPN22 TNF
10 inflammatory bowel disease 31.6 CTLA4 PTPN22 STAT4 TLR5 TNF
11 primary biliary cholangitis 31.5 CTLA4 PTPN22
12 diabetes mellitus 31.3 C4A CTLA4 MALAT1 PTPN22 TNF
13 systemic lupus erythematosus 1 12.6
14 systemic lupus erythematosus 2 12.6
15 systemic lupus erythematosus 9 12.5
16 systemic lupus erythematosus 10 12.5
17 systemic lupus erythematosus 6 12.5
18 systemic lupus erythematosus 11 12.5
19 systemic lupus erythematosus 3 12.4
20 systemic lupus erythematosus 4 12.4
21 systemic lupus erythematosus 5 12.4
22 systemic lupus erythematosus 7 12.4
23 systemic lupus erythematosus 12 12.4
24 neonatal systemic lupus erythematosus 12.3
25 systemic lupus erythematosus with hemolytic anemia 1 12.3
26 systemic lupus erythematosus 15 12.2
27 systemic lupus erythematosus with nephritis 1 12.2
28 systemic lupus erythematosus with nephritis 2 12.2
29 systemic lupus erythematosus with nephritis 3 12.2
30 systemic lupus erythematosus 8 12.2
31 systemic lupus erythematosus 13 12.2
32 systemic lupus erythematosus 14 12.2
33 neonatal lupus erythematosus 12.1
34 vitiligo-associated multiple autoimmune disease susceptibility 1 11.9
35 c1q deficiency 11.7
36 mixed connective tissue disease 11.7
37 behcet syndrome 11.5 C4A CTLA4 STAT4 TNF
38 multifocal motor neuropathy 11.5 BANK1 FCGR2B PTPN22
39 sympathetic ophthalmia 11.5 CTLA4 PDCD1 TNF
40 oligoarticular juvenile idiopathic arthritis 11.5 PTPN22 STAT4 TNF
41 severe hemophilia a 11.5 CTLA4 FCGR2A TNF
42 drug-induced lupus erythematosus 11.4
43 hypogonadotropic hypogonadism 11.4
44 pure red-cell aplasia 11.4
45 cutaneous lupus erythematosus 11.4
46 sjogren syndrome 11.4
47 macrophage activation syndrome 11.4
48 epidermolysis bullosa acquisita 11.4
49 immunodeficiency due to a classical component pathway complement deficiency 11.4 C4A C4B
50 renal tubular acidosis, distal 11.4

Comorbidity relations with Systemic Lupus Erythematosus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Neutropenia
Osteoporosis Postinflammatory Pulmonary Fibrosis
Raynaud Phenomenon Rheumatoid Arthritis
Sjogren Syndrome Systemic Scleroderma

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus:



Diseases related to Systemic Lupus Erythematosus

Symptoms & Phenotypes for Systemic Lupus Erythematosus

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
seizures
psychosis

Hematology:
hemolytic anemia
thrombocytopenia
leukopenia

Respiratory Lung:
pleuritis

Genitourinary Kidneys:
nephritis

Laboratory Abnormalities:
antiphospholipid antibody
anti dsdna antibody
serum antinuclear antibody

Skeletal Limbs:
arthritis

Cardiovascular Heart:
pericarditis

Immunology:
systemic lupus erythematosus

Skin Nails Hair Skin:
photosensitivity
erythematous malar rash
discoid rash


Clinical features from OMIM:

152700

Human phenotypes related to Systemic Lupus Erythematosus:

32 (show all 13)
# Description HPO Frequency HPO Source Accession
1 nephritis 32 HP:0000123
2 psychosis 32 HP:0000709
3 cutaneous photosensitivity 32 HP:0000992
4 seizures 32 HP:0001250
5 arthritis 32 HP:0001369
6 pericarditis 32 HP:0001701
7 thrombocytopenia 32 HP:0001873
8 hemolytic anemia 32 HP:0001878
9 leukopenia 32 HP:0001882
10 pleuritis 32 HP:0002102
11 systemic lupus erythematosus 32 HP:0002725
12 antinuclear antibody positivity 32 HP:0003493
13 antiphospholipid antibody positivity 32 HP:0003613

UMLS symptoms related to Systemic Lupus Erythematosus:


exanthema, pruritus, lupus-like rash, heliotrope rash, seizures

MGI Mouse Phenotypes related to Systemic Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 C4B CR2 CTLA4 DNASE1 ENG FCGR2A
2 homeostasis/metabolism MP:0005376 10.15 C4B CR2 CTLA4 DNASE1 ENG FCGR2B
3 immune system MP:0005387 10.13 BANK1 C4B CR2 CTLA4 DNASE1 FCGR2A
4 cardiovascular system MP:0005385 10.11 CTLA4 ENG FCGR2B PDCD1 PTPN22 TLR5
5 digestive/alimentary MP:0005381 10.03 C4B CTLA4 ENG FCGR2B PTPN22 TNF
6 mortality/aging MP:0010768 9.97 C4B CR2 CTLA4 DNASE1 ENG FCGR2A
7 liver/biliary system MP:0005370 9.86 C4B CTLA4 FCGR2B PDCD1 PTPN22 TLR5
8 renal/urinary system MP:0005367 9.56 DNASE1 FCGR2B PDCD1 PTPN22 STAT4 TREX1
9 respiratory system MP:0005388 9.23 CTLA4 ENG FCGR2B PDCD1 PTPN22 TLR5

Drugs & Therapeutics for Systemic Lupus Erythematosus

Drugs for Systemic Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
4-Aminopyridine Approved Phase 4 504-24-5 1727
3
Everolimus Approved Phase 4,Phase 2 159351-69-6 6442177
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
9
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
10
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 5284616 6436030 46835353
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
13
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 356547-88-1 5957 10451420
14
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
15
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 118-42-3 3652
16
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 50-78-2 2244
17
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
18
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
19
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
20
Lenalidomide Approved Phase 4 191732-72-6 216326
21
Sulfamethoxazole Approved Phase 4 723-46-6 5329
22
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
23
Thioguanine Approved Phase 4 154-42-7 2723601
24
Metformin Approved Phase 4 657-24-9 14219 4091
25
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
26
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
28
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 1406-16-2
31 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
33 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Rosuvastatin Calcium Phase 4,Phase 3,Phase 2,Phase 1 147098-20-2
38 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Potassium Channel Blockers Phase 4
40 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Antifungal Agents Phase 4,Phase 2,Phase 1,Not Applicable
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
47 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 583)
# Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Unknown status NCT02849782 Phase 4 Fampridine
5 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
6 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
7 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
8 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
9 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
10 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
11 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
12 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
13 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
14 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
15 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
16 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
17 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
18 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
19 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
20 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
21 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
22 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
23 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
24 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
25 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
26 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
27 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
28 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
29 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Recruiting NCT03098823 Phase 4 RAYOS;Prednisone
30 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
31 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
32 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
33 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4 Azathioprine
34 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
35 The Effect of Metformin on Reducing Lupus Flares Active, not recruiting NCT02741960 Phase 4 metformin;placebo
36 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
37 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
38 Safety and Immunogenicity of a Zoster Vaccine in SLE Active, not recruiting NCT02477150 Phase 4
39 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Not yet recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
40 Trial of Belimumab in Early Lupus Not yet recruiting NCT03543839 Phase 4
41 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
42 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
43 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
44 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
45 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
46 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
47 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
48 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
49 To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)
50 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy

Search NIH Clinical Center for Systemic Lupus Erythematosus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Lupus Erythematosus cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lupus erythematosus, systemic

Genetic Tests for Systemic Lupus Erythematosus

Genetic tests related to Systemic Lupus Erythematosus:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 29 BANK1 CTLA4 DNASE1 FCGR2A FCGR2B PTPN22 TREX1

Anatomical Context for Systemic Lupus Erythematosus

MalaCards organs/tissues related to Systemic Lupus Erythematosus:

41
T Cells, Skin, B Cells, Kidney, Heart, Endothelial, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Systemic Lupus Erythematosus:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Systemic Lupus Erythematosus

Articles related to Systemic Lupus Erythematosus:

(show top 50) (show all 7009)
# Title Authors Year
1
Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. ( 29951963 )
2018
2
Anti-tubulin-I+-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations. ( 29427009 )
2018
3
Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study. ( 29955369 )
2018
4
Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. ( 29979417 )
2018
5
The existential experience of everyday life with systemic lupus erythematosus. ( 29350776 )
2018
6
Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment. ( 28650277 )
2018
7
Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity. ( 29976042 )
2018
8
Bronchiolitis obliterans organising pneumonia as an initial manifestation in a patient with systemic lupus erythematosus: a rare presentation. ( 29804073 )
2018
9
Limbic Encephalitis in Association with Systemic Lupus Erythematosus. ( 29780149 )
2018
10
Prevalence and factors associated with fatigue in female patients with systemic lupus erythematosus. ( 29439873 )
2018
11
[Opportunistic infection in systemic lupus erythematosus patients: the disease spectrum and the characteristics of peripheral lymphocyte subsets]. ( 29325308 )
2018
12
Complement deficiency in pediatric-onset systemic lupus erythematosus. ( 29692593 )
2018
13
Association of angiotensin-converting enzyme insertion/deletion polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis. ( 29205894 )
2018
14
Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus. ( 29434811 )
2018
15
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. ( 29247540 )
2018
16
Systemic Lupus Erythematosus Presenting as Longitudinally Extensive Transverse Myelitis and Nephritis: A Case Report. ( 29872583 )
2018
17
Diffuse alveolar haemorrage as initial presentation of systemic lupus erythematosus: a case report. ( 28592199 )
2018
18
Women who had appendectomy have increased risk of systemic lupus erythematosus: a nationwide cohort study. ( 29971583 )
2018
19
A Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic Lupus Erythematosus is an Early Sign of Progressive Multifocal Leukoencephalopathy: A Clinicopathological Study. ( 29709947 )
2018
20
The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. ( 29796907 )
2018
21
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. ( 28659045 )
2018
22
Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. ( 29549933 )
2018
23
Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). ( 29121273 )
2018
24
Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. ( 28755788 )
2018
25
Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. ( 28480528 )
2018
26
CCR6<sup>+</sup>Th cell distribution differentiates systemic lupus erythematosus patients based on anti-dsDNA antibody status. ( 29441231 )
2018
27
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
28
Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood. ( 29868531 )
2018
29
Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. ( 29288864 )
2018
30
Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus. ( 29271374 )
2018
31
Exome sequencing revealed C1Q homozygous mutation in Pediatric Systemic Lupus Erythematosus. ( 29739689 )
2018
32
Autoimmune disease associated IFIH1 single nucleotide polymorphism related with IL-18 serum levels in Chinese systemic lupus erythematosus patients. ( 29930297 )
2018
33
Cytomegalovirus infection in a patient with systemic lupus erythematosus and acute myocardial infarction - cause or causal relationship? ( 29915649 )
2018
34
Increased incidence of cancer in systemic lupus erythematosus: a Finnish cohort study with more than 25 years of follow-up. ( 29318934 )
2018
35
Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. ( 29431056 )
2018
36
Clinical Factors Associated with Brain Volume Reduction in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations. ( 29449817 )
2018
37
Papilloedema and Autoimmune Retinopathy from Systemic Lupus Erythematosus. ( 29563958 )
2018
38
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. ( 29670626 )
2018
39
Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus. ( 29451069 )
2018
40
B-cell-depleting therapy for diffuse alveolar hemorrhage in systemic lupus erythematosus. ( 29907447 )
2018
41
Hospital-acquired infection in patients with systemic lupus erythematosus: a case-control study in a southern Chinese population. ( 29181727 )
2018
42
Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge. ( 29866760 )
2018
43
Impaired long-term immune protection following pneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE). ( 29444908 )
2018
44
Syncope caused by complete heart block and ventricular arrhythmia as early manifestation of systemic lupus erythematosus in a pregnant patient: a case report. ( 29954280 )
2018
45
Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. ( 29294596 )
2018
46
Association between PPP2CA polymorphisms and clinical features in southwest Chinese systemic lupus erythematosus patients. ( 29979448 )
2018
47
The interplay between tuberculosis and systemic lupus erythematosus. ( 29438163 )
2018
48
Systemic Lupus Erythematosus Presenting as Livedoid Vasculopathy over the Forearms. ( 29911533 )
2018
49
Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. ( 29963787 )
2018
50
Nervous system disease in Systemic Lupus Erythematosus: Current status and future directions. ( 29927108 )
2018

Variations for Systemic Lupus Erythematosus

UniProtKB/Swiss-Prot genetic disease variations for Systemic Lupus Erythematosus:

75
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601
2 TREX1 p.Arg114His VAR_028319 rs72556554
3 TREX1 p.Ala158Val VAR_037949 rs762011967
4 TREX1 p.Gly227Ser VAR_037950 rs113107733
5 TREX1 p.Arg240Ser VAR_037951 rs72556555
6 TREX1 p.Ala247Pro VAR_037952 rs112741962
7 TREX1 p.Pro290Leu VAR_037954 rs148833270
8 TREX1 p.Tyr305Cys VAR_037955 rs370504038
9 TREX1 p.Gly306Ala VAR_037956 rs780022923
10 TREX1 p.Asp200His VAR_070901

ClinVar genetic disease variations for Systemic Lupus Erythematosus:

6
(show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh37 Chromosome 3, 48508395: 48508395
2 TREX1 NM_033629.4(TREX1): c.341G> A (p.Arg114His) single nucleotide variant risk factor rs72556554 GRCh38 Chromosome 3, 48466996: 48466996
3 FCGR2B NM_004001.4(FCGR2B): c.-386G> C single nucleotide variant risk factor rs3219018 GRCh38 Chromosome 1, 161662856: 161662856
4 FCGR2B NM_004001.4(FCGR2B): c.-386G> C single nucleotide variant risk factor rs3219018 GRCh37 Chromosome 1, 161632646: 161632646
5 FCGR2B NM_004001.4(FCGR2B): c.695T> C (p.Ile232Thr) single nucleotide variant protective,risk factor rs1050501 GRCh37 Chromosome 1, 161643798: 161643798
6 FCGR2B NM_004001.4(FCGR2B): c.695T> C (p.Ile232Thr) single nucleotide variant protective,risk factor rs1050501 GRCh38 Chromosome 1, 161674008: 161674008
7 PTPN22 NM_015967.6(PTPN22): c.1858C> T (p.Arg620Trp) single nucleotide variant risk factor rs2476601 GRCh37 Chromosome 1, 114377568: 114377568
8 PTPN22 NM_015967.6(PTPN22): c.1858C> T (p.Arg620Trp) single nucleotide variant risk factor rs2476601 GRCh38 Chromosome 1, 113834946: 113834946
9 TNF TNF, -308G-A single nucleotide variant risk factor
10 FCGR2A NM_021642.3(FCGR2A): c.497A> G (p.His166Arg) single nucleotide variant drug response rs1801274 GRCh37 Chromosome 1, 161479745: 161479745
11 FCGR2A NM_021642.3(FCGR2A): c.497A> G (p.His166Arg) single nucleotide variant drug response rs1801274 GRCh38 Chromosome 1, 161509955: 161509955
12 DNASE1 NM_005223.3(DNASE1): c.13A> T (p.Lys5Ter) single nucleotide variant risk factor rs121912990 GRCh37 Chromosome 16, 3705387: 3705387
13 DNASE1 NM_005223.3(DNASE1): c.13A> T (p.Lys5Ter) single nucleotide variant risk factor rs121912990 GRCh38 Chromosome 16, 3655386: 3655386
14 DNASE1 NM_005223.3(DNASE1): c.731G> A (p.Arg244Gln) single nucleotide variant risk factor rs1053874 GRCh37 Chromosome 16, 3707747: 3707747
15 DNASE1 NM_005223.3(DNASE1): c.731G> A (p.Arg244Gln) single nucleotide variant risk factor rs1053874 GRCh38 Chromosome 16, 3657746: 3657746
16 ENG NM_000118.3(ENG): c.816+6T> C single nucleotide variant Pathogenic rs759191907 GRCh38 Chromosome 9, 127825225: 127825225
17 ENG NM_000118.3(ENG): c.816+6T> C single nucleotide variant Pathogenic rs759191907 GRCh37 Chromosome 9, 130587504: 130587504

Copy number variations for Systemic Lupus Erythematosus from CNVD:

7 (show all 43)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14694 1 110000000 163800000 Gain or loss FCGR3B Systemic lupus erythematosus
2 21050 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
3 21051 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
4 21053 1 156500000 165500000 Copy number FCGR3B Systemic lupus erythematosus
5 21628 1 159859611 159867782 Copy number FCGR3B Systemic lupus erythematosus
6 21630 1 159859611 159867782 Low copy number FCGR3B Systemic lupus erythematosus
7 21794 1 161592989 161601158 Copy number FCGR3B Systemic lupus erythematosus
8 21797 1 161592989 161601158 Deletion FCGR3B Systemic lupus erythematosus
9 107133 17 1225928 31649829 Copy number CCL3L3 Systemic lupus erythematosus
10 107143 17 1225928 31649843 Copy number CCL3L1 Systemic lupus erythematosus
11 107163 17 1242109 31665953 Copy number CCL4L2 Systemic lupus erythematosus
12 110232 17 31562580 31665959 Copy number CCL4L1 Systemic lupus erythematosus
13 110282 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
14 110283 17 31800000 38100000 Copy number CCL3L1 Systemic lupus erythematosus
15 110288 17 31800000 38100000 Copy number CCL4L1 Systemic lupus erythematosus
16 112168 17 38100000 38400000 Copy number CCL3L1 Systemic lupus erythematosus
17 113342 17 43165608 43178484 Amplification T-bet Systemic lupus erythematosus
18 162470 22 21800000 24300000 Gain or loss GSTT1 Systemic lupus erythematosus
19 186012 4 2713184 2727859 Deletion TNIP2 Systemic lupus erythematosus
20 196060 5 158674368 158690059 Amplification IL-12B Systemic lupus erythematosus
21 204042 6 105500000 114600000 Copy number C4A Systemic lupus erythematosus
22 204043 6 105500000 114600000 Copy number C4B Systemic lupus erythematosus
23 207132 6 15200000 46200000 Copy number Systemic lupus erythematosus
24 209409 6 2614953 31491069 Copy number MICA Systemic lupus erythematosus
25 210235 6 29900000 36800000 Low copy numbers C4 Systemic lupus erythematosus
26 210494 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
27 210495 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
28 210499 6 30400000 36600000 Copy number C4A Systemic lupus erythematosus
29 210506 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
30 210507 6 30400000 36600000 Copy number C4B Systemic lupus erythematosus
31 210512 6 30400000 36600000 Gain C4A Systemic lupus erythematosus
32 210513 6 30400000 36600000 Gain C4B Systemic lupus erythematosus
33 211033 6 31949833 32003194 Copy number C4A Systemic lupus erythematosus
34 211045 6 3197570 32111174 Copy number C4A Systemic lupus erythematosus
35 211049 6 3197570 32111174 Duplication C4 Systemic lupus erythematosus
36 211054 6 31982571 32003194 Copy number C4B Systemic lupus erythematosus
37 211360 6 32593131 32665540 Copy number HLA-DRB5 Systemic lupus erythematosus
38 212285 6 3674895 32665540 Copy number HLA-DRB1 Systemic lupus erythematosus
39 212431 6 3795995 32719407 Copy number HLA-DQA1 Systemic lupus erythematosus
40 212452 6 3813334 32742444 Copy number HLA-DQB1 Systemic lupus erythematosus
41 212671 6 40500000 46200000 Copy number Systemic lupus erythematosus
42 212678 6 40500000 93100000 Copy number Systemic lupus erythematosus
43 243031 8 7752198 7754236 Copy number DEFB4 Systemic lupus erythematosus

Expression for Systemic Lupus Erythematosus

LifeMap Discovery
Genes differentially expressed in tissues of Systemic Lupus Erythematosus patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 5.47 0.000
2 OTOF otoferlin Blood + 5.25 0.000
3 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood - 4.40 0.000
4 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Blood + 4.22 0.000
5 LINC00661 long intergenic non-protein coding RNA 661 Blood + 4.15 0.000
6 SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin Blood + 4.12 0.000
7 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood - 3.96 0.000
8 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.81 0.000
9 IFI44L interferon-induced protein 44-like Blood + 3.58 0.000
10 USP41 ubiquitin specific peptidase 41 Blood + 3.40 0.000
11 HESX1 HESX homeobox 1 Blood + 3.22 0.000
12 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Blood + 3.08 0.000
Search GEO for disease gene expression data for Systemic Lupus Erythematosus.

Pathways for Systemic Lupus Erythematosus

Pathways related to Systemic Lupus Erythematosus according to KEGG:

37
# Name Kegg Source Accession
1 Systemic lupus erythematosus hsa05322

GO Terms for Systemic Lupus Erythematosus

Cellular components related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 CTLA4 ENG FCGR2B PDCD1 TNF

Biological processes related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of complement activation GO:0030449 9.61 C4A C4B CR2
2 inflammatory response GO:0006954 9.55 C4A C4B FCGR2B TLR5 TNF
3 negative regulation of B cell proliferation GO:0030889 9.4 CTLA4 FCGR2B
4 regulation of innate immune response GO:0045088 9.37 FCGR2B PTPN22
5 negative regulation of B cell activation GO:0050869 9.32 BANK1 FCGR2B
6 negative regulation of interleukin-6 secretion GO:1900165 9.26 BANK1 PTPN22
7 immune system process GO:0002376 9.1 C4A C4B CR2 CTLA4 PTPN22 TLR5
8 positive regulation of apoptotic cell clearance GO:2000427 8.96 C4A C4B

Molecular functions related to Systemic Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase binding GO:1990782 9.16 BANK1 PTPN22
2 IgG binding GO:0019864 8.96 FCGR2A FCGR2B
3 complement binding GO:0001848 8.62 C4B CR2

Sources for Systemic Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....